These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22239669)

  • 21. Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.
    Correa JG; Cibeira MT; Tovar N; Isola I; Pedrosa F; Díaz T; Lozano E; Magnano L; Rosiñol L; Bladé J; Fernández de Larrea C
    Br J Haematol; 2017 Dec; 179(5):849-851. PubMed ID: 27605200
    [No Abstract]   [Full Text] [Related]  

  • 22. The incidence and survival of Waldenström's Macroglobulinaemia in South East England.
    Phekoo KJ; Jack RH; Davies E; Møller H; Schey SA;
    Leuk Res; 2008 Jan; 32(1):55-9. PubMed ID: 17416416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Waldenström's macroglobulinemia: incidence patterns in the United States, 1988-1994.
    Groves FD; Travis LB; Devesa SS; Ries LA; Fraumeni JF
    Cancer; 1998 Mar; 82(6):1078-81. PubMed ID: 9506352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Primary macroglobulinemia in Japan].
    Miyoshi K; Numata Y; Saijo K; Shiragami A; Miyake M
    Nihon Rinsho; 1970 Aug; 28(8):2040-5. PubMed ID: 4989857
    [No Abstract]   [Full Text] [Related]  

  • 25. Head and neck chondrosarcomas: Analysis of the Surveillance, Epidemiology, and End Results database.
    Ellis MA; Gerry DR; Byrd JK
    Head Neck; 2016 Sep; 38(9):1359-66. PubMed ID: 27042949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistent socioeconomic inequalities in cancer survival in the United States: 1973-2007 surveillance, epidemiology and end results (SEER) data for breast cancer and non-Hodgkin's lymphoma.
    Kato I; Booza J; Quarshie WO; Schwartz K
    J Registry Manag; 2012; 39(4):158-66. PubMed ID: 23493021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Frequency of macroglobulinemia and its clinicopathological evaluation].
    Kitazumi T; Miura H; Ozawa M; Sakurabayashi I
    Rinsho Byori; 1974 Oct; 22(10 Suppl):179. PubMed ID: 4217395
    [No Abstract]   [Full Text] [Related]  

  • 28. Smouldering Waldenstrom's macroglobulinemia: factors predicting evolution to symptomatic disease.
    Cesana C; Miqueleiz S; Bernuzzi P; Tresoldi E; Rossi V; D'avanzo G; Filippini D; Morra E
    Semin Oncol; 2003 Apr; 30(2):231-5. PubMed ID: 12720142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiation therapy improves survival in rectal small cell cancer - Analysis of Surveillance Epidemiology and End Results (SEER) data.
    Modrek AS; Hsu HC; Leichman CG; Du KL
    Radiat Oncol; 2015 Apr; 10():101. PubMed ID: 25902707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: a preliminary study.
    Ojha RP; Hanzis CA; Hunter ZR; Greenland S; Offutt-Powell TN; Manning RJ; Lewicki M; Brodsky PS; Ioakimidis L; Tripsas CK; Patterson CJ; Sheehy P; Singh KP; Treon SP
    Cancer Epidemiol; 2012 Jun; 36(3):294-7. PubMed ID: 22099500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan.
    Saito A; Isoda A; Kojima M; Yokohama A; Tsukune Y; Sasaki M; Ito S; Ohtsu A; Koike M; Murayama K; Moriya K; Tamura H; Matsumoto M; Nakahashi H; Tanosaki S; Sakura T; Kawamura T; Miyanaga T; Nakamura N; Murakami H; Handa H; Tsukamoto N
    Int J Hematol; 2017 Nov; 106(5):681-690. PubMed ID: 28687991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia.
    Poulain S; Roumier C; Venet-Caillault A; Figeac M; Herbaux C; Marot G; Doye E; Bertrand E; Geffroy S; Lepretre F; Nibourel O; Decambron A; Boyle EM; Renneville A; Tricot S; Daudignon A; Quesnel B; Duthilleul P; Preudhomme C; Leleu X
    Clin Cancer Res; 2016 Mar; 22(6):1480-8. PubMed ID: 26490317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia.
    Castillo JJ; Gustine J; Meid K; Dubeau T; Hunter ZR; Treon SP
    Am J Hematol; 2016 Oct; 91(10):1032-5. PubMed ID: 27415417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Kyriakou C; Canals C; Cornelissen JJ; Socié G; Willemze R; Ifrah N; Greinix HT; Blaise D; Deconinck E; Ferrant A; Schattenberg A; Harousseau JL; Sureda A; Schmitz N
    J Clin Oncol; 2010 Nov; 28(33):4926-34. PubMed ID: 20956626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinct characteristics and new prognostic scoring system for Chinese patients with Waldenström macroglobulinemia.
    Yi S; Cui R; Li Z; An G; Qi J; Zou D; Zhang P; Chen H; Wang J; Chang H; Qiu L
    Chin Med J (Engl); 2014; 127(12):2327-31. PubMed ID: 24931251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of lymphoplasmacytic lymphoma/Waldenström's macroglobulinaemia in Japan and Taiwan population-based cancer registries, 1996-2003.
    Iwanaga M; Chiang CJ; Soda M; Lai MS; Yang YW; Miyazaki Y; Matsuo K; Matsuda T; Sobue T
    Int J Cancer; 2014 Jan; 134(1):174-80. PubMed ID: 23784625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.
    Treon SP; Gustine J; Xu L; Manning RJ; Tsakmaklis N; Demos M; Meid K; Guerrera ML; Munshi M; Chan G; Chen J; Kofides A; Patterson CJ; Yang G; Liu X; Severns P; Dubeau T; Hunter ZR; Castillo JJ
    Br J Haematol; 2018 Feb; 180(3):374-380. PubMed ID: 29181840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis.
    Go RS; Gundrum JD; Neuner JM
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):177-186.e4. PubMed ID: 25445471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010.
    Zeng C; Wen W; Morgans AK; Pao W; Shu XO; Zheng W
    JAMA Oncol; 2015 Apr; 1(1):88-96. PubMed ID: 26182310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia.
    Leblebjian H; Noonan K; Paba-Prada C; Treon SP; Castillo JJ; Ghobrial IM
    Am J Hematol; 2015 Jun; 90(6):E122-3. PubMed ID: 25703132
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.